drugset / Trial / NCT00800345

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

NCT00800345

Phase 1 Completed 33 enrolled Vector Oncology GlaxoSmithKline · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, dose-escalation study in female patients with recurrent or persistent gynecologic tumors.

Timeline

Start
2009-04
Primary completion
2015-06
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule Oral
Subject Topotecan Small molecule Oral